Human physiologically based pharmacokinetic model for ACE inhibitors: Ramipril and ramiprilat

BMC Clinical Pharmacology

Volumn 6, Issue , 2006, Pages

  Levitt, David G ^a   Schoemaker, Rik C ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; RAMIPRIL; RAMIPRILAT; SODIUM CHLORIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE;

ACCURACY; ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BOLUS INJECTION; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE PERMEABILITY; COMPUTER PROGRAM; DILUTION; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG INFUSION; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG UPTAKE; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; KIDNEY CLEARANCE; KIDNEY METABOLISM; LIVER METABOLISM; MALE; MATHEMATICAL COMPUTING; NORMAL HUMAN; RADIOIMMUNOASSAY; RECEPTOR AFFINITY; BINDING SITE; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; ENZYME SPECIFICITY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY;

ADMINISTRATION, ORAL; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BINDING SITES; BIOLOGICAL AVAILABILITY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PEPTIDYL-DIPEPTIDASE A; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY;

EID: 30644460910     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-6-1     Document Type: Article

References (73)

1. Levitt DG: PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics. BMC Clin Pharmacol 2002, 2(1):7.
2. Levitt DG: PKQuest: volatile solutes - application to enflurane, nitrous oxide, halothane, methoxyflurane and toluene pharmacokinetics. BMC Anesthesiol 2002, 2(1):5.
3. Levitt DG: PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics. BMC Clin Pharmacol 2002, 2(1):4.
4. Levitt DG: PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol 2002, 2(1):5.
5. Levitt DG: The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption. BMC Clin Pharmacol 2003, 3(1):1.
6. Levitt DG: The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 2003, 3(1):3.
7. Levitt DG: Physiologically based pharmacokinetic modeling of arterial - antecubital vein concentration difference. BMC Clin Pharmacol 2004, 4(1):2.
8. Levitt DG, Schnider TW: Human physiologically based pharmacokinetic model for propofol. BMC Anesthesiol 2005, 5(1):4.
9. Dzau VJ, Bernstein & Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M: The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001, 88(9A):1L-20L.
10. Pinto YM, van Veldhuisen DJ, Tjon-Ka-Jie RT, Rooks G, Netzer T, Lie KI: Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Eur J Clin Pharmacol 1996, 50(4):265-268.
11. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther 1995, 275(2):854-863.
12. Chevillard C, Brown NL, Mathieu MN, Laliberte F, Worcel M: Differential effects of oral trandolapril and enalapril on rat tissue angiotensin-converting enzyme. Eur J Pharmacol 1988, 147(1):23-28.
13. Roffman DS: High-versus low-dose ACE inhibitor therapy in chronic heart failure. Ann Pharmacother 2004, 38(5):831-838.
14. Shapiro R, Riordan JF: Inhibition of angiotensin converting enzyme: dependence on chloride. Biochemistry 1984, 23(22):5234-5240.
15. Bull HG, Thornberry NA, Cordes MH, Patchett AA, Cordes EH: Inhibition of rabbit lung angiotensin-converting enzyme by N alpha-[(S)-1-carboxy-3-phenylpropyl]L-alanyl-L-proline and N alpha-[(S)-1-carboxy-3-phenylpropyl]L-lysyl-L-proline. J Biol Chem 1985, 260(5):2952-2962.
16. Goli UB, Galardy RE: Kinetics of slow, tight-binding inhibitors of angiotensin converting enzyme. Biochemistry 1986, 25(22):7136-7142.
17. Ryan JW, Chung AY, Berryer P, Murray MA, Ryan JP: Slow tight binding inhibitors of angiotensin converting enzyme. Adv Exp Med Biol 1986, 198 Pt A:419-425.
18. Bunning P: Kinetic properties of the angiotensin converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol 1987, 10 Suppl 7:S31-35.
19. Wei L, Clauser E, Alhenc-Gelas F, Corvol P: The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992, 267(19):13398-13405.
20. Skirgello OE, Binevski PV, Pozdnev VF, Kost OA: Kinetic probes for interdomain cooperation in human somatic angiotensin-converting enzyme. Biochem J 2005.
21. Deddish PA, Wang LX, Jackman HL, Michel B, Wang J, Skidgel RA, Erdos EG: Single-domain angiotensin I converting enzyme (kininase II): characterization and properties. J Pharmacol Exp Ther 1996, 279(3):1582-1589.
22. Skoglof A, Gothe PO, Deinum J: Effect of temperature and chloride on steady-state inhibition of angiotensin I-converting enzyme by enalaprilat and ramiprilat. Biochem J 1990, 272(2):415-419.
23. Jackson B, Cubela R, Johnston C: Angiotensin converting enzyme (ACE), characterization by 1251-MK351A binding studies of plasma and tissue ACE during variation of salt status in the rat. J Hypertens 1986, 4(6):759-765.
24. Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V: Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res 2003, 93(2):148-154.
25. Bevilacqua M, Vago T, Rogolino A, Conci F, Santoli E, Norbiato G: Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. J Cardiovasc Pharmacol 1996, 28(4):494-499.
26. Fabris B, Chen BZ, Pupic V, Perich R, Johnston CI: Inhibition of angiotensi-converting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol 1990, 15 Suppl 2:S6-13.
27. Johnston CI, Fabris B, Yamada H, Mendelsohn FA, Cubela R, Sivell D, Jackson B: Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989, 7(5):S 11-16.
28. Beldent V, Michaud A, Wei L, Chauvet MT, Corvol P: Proteolytic release of human angiotensin-converting enzyme. Localization of the cleavage site. J Biol Chem 1993, 268(35):26428-26434.
29. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86(4):1343-1346.
30. King JN, Maurer M, Toutain PL: Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. J Vet Pharmacol Ther 2003, 26(3):213-224.
31. Toutain PL, Lefebvre HP, King JN: Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. J Pharmacol Exp Ther 2000, 292(3):1087-1093.
32. Toutain PL, Lefebvre HP: Pharmacokinetics and pharmacokinetic/ pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. J Vet Pharmacol Ther 2004, 27(6):515-525.
33. Francis RJ, Brown AN, Kler L, Fasanella d'Amore T, Nussberger J, Waeber B, Brunner HR: Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol 1987, 9(1):32-38.
34. Lees KR, Kelman AW, Reid JL, Whiting B: Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. J Pharmacokinet Biopharm 1989, 17(5):529-550.
35. Brockmeier D: Tight binding of ramiprilat to ACE: consequences for pharmacokinetic and pharmacodynamic measurements. Int J Clin Pharmacol Ther 1995, 33(12):631-638.
36. Brockmeier D: Tight binding influencing the future of pharmacokinetics. Methods Find Exp Clin Pharmacol 1998, 20(6):505-516.
37. PKQuest: One stop pharmacokinetic program. http://www.pkquest.com]
38. van Griensven JM, Schoemaker RC, Cohen AF, Luus HG, Seibert-Grafe M, Rothig HJ: Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. Eur J Clin Pharmacol 1995, 47(6):513-518.
39. Thuillez C, Richer C, Giudicelli JF: Pharmacokinetics, converting enzyme inhibition and peripheral arterial hemodynamics of ramipril in healthy volunteers. Am J Cardiol 1987, 59(10):38D-44D.
40. Zeitz CJ, Campbell DJ, Horowitz JD: Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans. Hypertension 2003, 41(3):482-487.
41. Eckert HG, Badian MJ, Gantz D, Kellner HM, Volz M: Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arzneimittelforschung 1984, 34(10B): 1435-1447.
42. Ranadive SA, Chen AX, Serajuddin AT: Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res 1992, 9(11):1480-1486.
43. Abu-Zahra TN, Wolkoff AW, Kim RB, Pang KS: Uptake of enalapril and. expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos 2000, 28(7):801-806.
44. Liu L, Pang KS: The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos 2005, 33(1):1-9.
45. de Lannoy IA, Barker F, 3rd, Pang KS: Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver. J Pharmacokinet Biopharm 1993, 21(4):395-422.
46. de Lannoy IA, Hirayama H, Pang KS: A physiological model for renal drug metabolism: enalapril esterolysis to enalaprilat in the isolated perfused rat kidney. J Pharmacokinet Biopharm 1990, 18(6):561-587.
47. de Lannoy IA, Pang KS: Combined recirculation of the rat liver and kidney: studies with enalapril and enalaprilat. J Pharmacokinet Biopharm 1993, 21(4):423-456.
48. Pang KS, Cherry WF, Ulm EH: Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect. J Pharmacol Exp Ther 1985, 233(3):788-795.
49. Sirianni GL, Pang KS: Intracellular and not intraluminal esterolysis of enalapril in kidney. Studies with the single pass perfused nonfiltering rat kidney. Drug Metab Dispos 1998, 26(4):324-331.
50. Friedman DI, Amidon GL: Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Pharm Res 1989, 6(12):1043-1047.
51. Morrison RA, Chong S, Marino AM, Wasserman MA, Timmins P, Moore VA, Irwin WJ: Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies. Pharm Res 1996, 13(7):1078-1082.
52. Alhenc-Gelas F, Weare JA, Johnson RL, Jr., Erdos EG: Measurement of human converting enzyme level by direct radioimmunoassay. J Lab Clin Med 1983, 101(1):83-96.
53. Hattori MA, Del Ben GL, Carmona AK, Casarini DE: Angiotensin I-converting enzyme isoforms (high and low molecular weight) in urine of premature and full-term infants. Hypertension 2000, 35(6):1284-1290.
54. Cushman DW, Cheung HS: Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta 1971, 250(1):261-265.
55. Hwang DR, Eckelman WC, Mathias CJ, Petrillo EW, Jr., Lloyd J, Welch MJ: Positron-labeled angiotensin-converting enzyme (ACE) inhibitor: fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography. J Nucl Med 1991, 32(9):1730-1737.
56. Morin JP, Moulin B, Borghi H, Fillastre JP: High affinity binding sites for Perindopril a new inhibitor of angiotensin-I-converting enzyme (ACE) in the rabbit kidney: possible evidence for localization of ACE in endothelial structures and in glomerular mesangium. Int J Tissue React 1989, 11(2):81-92.
57. Reneland R, Haenni A, Andersson PE, Andren B, Lithell H: Skeletal muscle angiotensin-converting enzyme and its relationship to blood pressure in primary hypertension and healthy elderly men. Blood Press 1999, 8(1):16-22.
58. Reneland R, Lithell H: Angiotensin-converting enzyme in human skeletal muscle. A simple in vitro assay of activity in needle biopsy specimens. Scand J Clin Lab Invest 1994, 54(2):105-111.
59. Sakaguchi K, Jackson B, Chai SY, Mendelsohn FA, Johnson CI: Effects of perindopril on tissue angiotensin-converting enzyme activity demonstrated by quantitative in vitro autoradiography. J Cardiovasc Pharmacol 1988, 12(6):710-717.
60. Sun Y, Diaz-Arias AA, Weber KT: Angiotensin-converting enzyme, bradykinin, and angiotensin II receptor binding in rat skin, tendon, and heart valves: an in vitro, quantitative autoradiographic study. J Lab Clin Med 1994, 123(3):372-377.
61. Jonsson JR, Game PA, Head RJ, Frewin DB: The expression and localisation of the angiotensin-converting enzyme mRNA in human adipose tissue. Blood Press 1994, 3(1-2):72-75.
62. Nussberger J, Juillerat L, Perret F, Waeber B, Bellet M, Brunner J, Menard J: Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. Am Heart J 1989, 117(3):717-722.
63. Weisser K, Schloos J: Measurements of serum ACE activity in vitro after administration of enalapril in man cannot reflect inhibition of the enzyme in vivo. Methods Find Exp Clin Pharmacol 1993, 15(6):413-418.
64. van Griensven JM, Seibert-Grafe M, Schoemaker HC, Frolich M, Cohen AF: The pharmarokinetic and pharmacodynamic interactions of ramipril with propranolol. Eur J Clin Pharmacol 1993, 45(3):255-260.
65. Verho M, Luck C, Stelter WJ, Rangoonwala B, Bender N: Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Curr Med Res Opin 1995, 13(5):264-273.
66. Wei L, Alhenc-Gelas F, Corvol P, Clauser E: The two homologous domains of human angiotensin 1-converting enzyme are both catalytically active. J Biol Chem 1991, 266(14):9002-9008.
67. Nordstrom M, Abrahamsson T, Ervik M, Forshult E, Regardh CG: Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. J Pharmacol Exp Ther 1993, 266(1):147-152.
68. Schunkert H, Kindler J, Gassmann M, Lahn W, Irmisch R, Ritz E, Debusmann ER, Pujadas JO, Koch KM, Sieberth HG: Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. Eur J Clin Pharmacol 1989, 37(3):249-256.
69. Shionoiri H, Miyakawa T, Yasuda G, Ishikawa Y, Umemura S, Miyajima E, Kaneko Y: Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension. J Cardiovasc Pharmacol 1987, 10 Suppl 7:S145-147.
70. Aurell M, Delin K, Herlitz H, Ljungman S, Witte PU, Irmisch R: Pharmacokinetics and pharmacodynamics of ramipril in renal failure. Am J Cardiol 1987, 59(10):65D-69D.
71. Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jane F, Kuan TS, Mora J, Walter U, Eckert HG, Hajdu P, Metzger H: Influence of renal function on the pharmacokinetics of ramipril (HOE 498). Am J Cardiol 1987, 59(10):70D-72D.
72. Jaspard E, Wei L, Albenc-Gelas F: Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993, 268(13):9496-9503.
73. Heintz B, Verho M, Brockmeier D, Luckel G, Maigatter S, Sieberth HG, Rangoonwala B, Bender N: Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart faifure. J Cardiovasc Pharmacol 1993, 22 Suppl 9:S36-42.